Boehringer Ingelheim and Isis combine cell adhesion programs in $100 mil. agreement.
BOEHRINGER INGELHEIM AND ISIS COMBINE CELL ADHESION PROGRAMS WORTH $100 MIL. to the antisense firm in a letter of intent agreement. The collaboration, announced March 1, would combine Boehringer Ingelheim and Isis' clinical and research programs aimed at developing cell-adhesion targeted drugs. The cell adhesion alliance is subject to a definitive agreement that the companies say is expected to close in the second quarter. B-I's financial advisor for the transaction is Vector Securities.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth